Rezafungin—Mechanisms of Action, Susceptibility and Resistance: Similarities and Differences with the Other Echinocandins [PDF]
Journal of Fungi (Basel, Switzerland), 2020 Rezafungin (formerly CD101) is a new β-glucan synthase inhibitor that is chemically related with anidulafungin. It is considered the first molecule of the new generation of long-acting echinocandins. It has several advantages over the already approved by
Guillermo Garcia-Effron
exaly +8 more sources
Efficacy of rezafungin in a case of Candida spondylodiskitis [PDF]
Journal of Bone and Joint InfectionRezafungin, which only requires weekly administration, is a potential candidate for difficult-to-treat infections that require long-term antimicrobial treatment, such as bone and joint infections.
M. Lahouati +9 more
doaj +8 more sources
Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy [PDF]
Pharmacology Research and Perspectives, 2019 Rezafungin acetate is a novel echinocandin in clinical development for prevention and treatment of invasive fungal infections. Rezafungin is differentiated by a pharmacokinetic/pharmacodynamic (PK/PD) profile that includes a long half‐life allowing once ...
Voon Ong
exaly +4 more sources
Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data [PDF]
Journal of Fungi (Basel, Switzerland), 2020 Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique ...
Yanan Zhao, David S Perlin
exaly +5 more sources
Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
Microbiology Spectrum, 2023 Rezafungin is a novel once-weekly echinocandin for intravenous injection currently in development for the treatment of Candida infections and the prevention of Candida, Aspergillus, and Pneumocystis infections in allogeneic blood and marrow transplant ...
Shawn Flanagan, Helen Walker, Voon Ong
exaly +5 more sources
It’s Here, It’s There, There’s Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive Candidiasis [PDF]
Infectious Diseases and TherapyRezafungin is a long-acting echinocandin with broad coverage against Candida. Rezafungin has primarily been indicated for candidemia, with limited literature available on its use for infections outside of the bloodstream.
J. Myles Keck
exaly +3 more sources
Clinical Significance of Drug–Drug Interaction Studies During Therapeutic Peptide Drug Development: Follow‐Up Investigation of Therapeutic Peptides Approved Between 2021 and 2024 [PDF]
Clinical and Translational ScienceThe risk of clinically relevant drug–drug interactions (DDIs) for therapeutic peptides remains unclear, mandating a comprehensive analysis for this modality.
Carolina Säll +6 more
doaj +3 more sources
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician [PDF]
Infection and Drug Resistance, 2023 Frederic Lamoth1,2 1Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 2Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University ...
Lamoth F
doaj +3 more sources
Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial [PDF]
Clinical Infectious Diseases, 2021 BackgroundRezafungin (RZF) is a novel echinocandin exhibiting distinctive pharmacokinetics/pharmacodynamics. STRIVE was a phase 2, double-blind, randomized trial designed to compare the safety and efficacy of RZF once weekly (QWk) to caspofungin (CAS ...
George R Thompson +2 more
exaly +3 more sources
Journal of Fungi (Basel, Switzerland), 2021 Rezafungin is a novel echinocandin in Phase 3 development for prevention of invasive fungal disease caused by Candida spp., Aspergillus spp. and Pneumocystis jirovecii in blood and marrow transplantation patients.
Melanie T Cushion, Alan Ashbaugh
exaly +3 more sources